Lucentis
(ranibizumab)ApprovedMonoclonal antibody
RocheRanibizumab is used to treat eye diseases that cause vision loss, particularly wet age-related macular degeneration and diabetic eye disease, by blocking a protein that causes abnormal blood vessel growth in the eye.[2] Lucentis is currently approved and in use across 48 indications[4].[1]
Lucentis is one of 506 small molecule programs targeting Choroidal Neovascularization. It is currently in Approved.
48
Indications
402
Total Trials
5
Active Trials
505
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 47 indications
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Lucentis
RocheApproved
Taxol
TevaPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Eylea
RegeneronPhase 3
ABP 234
AmgenPhase 3
Epacadostat
IncytePhase 3
Interferon-Alpha-2a
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Cancervax Vaccine (CANVAXIN)
CCancerVax Corporation
Phase 3
Intron a
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration33 trials
Show 30 more trials
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
Terminated·—·Phase 2·NCT01189019·40 enrolled
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
Terminated·—·Phase 4·NCT00423189·7 enrolled
Diabetic Macular Edema26 trials
Show 23 more trials
Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
Terminated·—·Phase 4·NCT02665689·4 enrolled
Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
Completed·—·Phase 1/2·NCT00440609·50 enrolled
Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)
Unknown status·TThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·Phase 2/3·NCT00885794·40 enrolled
MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)
Completed·EEspecialistas en Retina Medica y Quirurgica Grupo de Investigacion·Phase 2·NCT01112085·72 enrolled
Retinal Vein Occlusion23 trials
Show 20 more trials
Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
Completed·—·Phase 4·NCT01448018·45 enrolled
Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
Completed·—·N/A·NCT02144662·50 enrolled
Choroidal Neovascularization8 trials
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT04922151·60 enrolled
Show 5 more trials
Treatment7 trials
49 more indications
Efficacy and Safety7 trials
Show 4 more trials
Macular Degeneration7 trials
Show 4 more trials
Proliferative Diabetic Retinopathy6 trials
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT04464694·142 enrolled
Wet Age-Related Macular Degeneration6 trials
Show 3 more trials
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT00813891·180 enrolled
Polypoidal choroidal vasculopathy5 trials
Safety and Efficacy4 trials
Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02810808·115 enrolled
Diabetes Mellitus3 trials
Neovascular3 trials
Optical Coherence Tomography3 trials
Macular Edema3 trials
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
Terminated·—·Phase 2·NCT00668785·6 enrolled
Diabetic Retinopathy3 trials
Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
Completed·—·Phase 3·NCT00545870·30 enrolled
Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
Unknown status·—·Phase 3·NCT05138029·60 enrolled
Intravitreal Injections2 trials
Dexamethasone2 trials
Coagulation2 trials
Glaucoma2 trials
Cystoid Macular Edema1 trial
Von Hippel-Lindau Syndrome1 trial
Pterygium1 trial
Combination Therapy1 trial
Randomised Controlled Trial1 trial
Retinopathy1 trial
Complication1 trial
MCI1 trial
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Unknown status·—·Phase 2/3·NCT04460001·100 enrolled
Tocilizumab1 trial
Concentration1 trial
Pathological Myopia1 trial
Wet Macular Degeneration1 trial
Neovascular AMD1 trial
Inflammation1 trial
Non-Proliferative Diabetic Retinopathy1 trial
Macula Edema1 trial
Retinal Diseases1 trial
Unspecified12 trials
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
Completed·—·Phase 1·NCT00749021·40 enrolled
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Completed·—·Phase 4·NCT00533520·37 enrolled
Show 9 more trials
Lucentis to Treat Pigment Epithelial Detachment
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00841581·32 enrolled
Lucentis KAV Study
Completed·TThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·Phase 3·NCT01570608·51 enrolled
Regulatory
FDA Approval Timeline[5]
Jun 30, 2006
LUCENTIS
BLA BLA125156
Oct 22, 2021
SUSVIMO
BLA BLA761197
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lucentis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for ranibizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]